Glanatec(R) 3 times a day for Fuchs' Dystrophy

Phase 4

Recruiting

Research Sponsored by Marian Macsai, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

This trial will investigate whether the drug Glanatec can be used to treat Fuchs endothelial dystrophy without a corneal transplant.

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Corneal Clearing

pachymetry measurement

Secondary study objectives

Visual Acuity

2Treatment groups

Active Control

Group I: Glanatec(R) 3 times a dayActive Control1 Intervention

Group II: Glanatec (R) 6 times a dayActive Control1 Intervention

Do I qualify?Apply below to find out

Marian Macsai, MDLead Sponsor

~4 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.